Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Orum Therapeutics

Private
#Oncology#Rare Disease

Cell-specific targeted protein degraders (TPD2) and stabilizers (TPS2) built on antibody conjugation, including ORM-5029 for HER2-expressing solid tumors.

Company Info

Sector:Biotechnology / Targeted Protein Degradation
Headquarters:Daejeon, South Korea
Founded:2016
Website:www.orumrx.com/

Clinical Development Pipeline

ORM-5029

Target: GSPT1 degrader conjugated to an anti-HER2 antibody
HER2-expressing solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

ORM-6151

Target: CD33 antibody-enabled GSPT1 degrader
Acute myeloid leukemia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

ORM-1153

Target: BCMA antibody-enabled degrader
Multiple myeloma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

See all open roles

Careers
Daejeon, South Korea
Apply Now →